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SCIENTIFIC REPORT
Upregulation of T-bet expression in peripheral blood
mononuclear cells during Vogt-Koyanagi-Harada disease
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Aim: To test the hypothesis that T-bet expression is altered in
patients with Vogt-Koyanagi-Harada (VKH) disease.
Methods: Peripheral blood was withdrawn from 16 VKH
patients before and after immunosuppressive treatment and
from 16 healthy individuals. IFN-c, IL-2, and IL-4 in the serum
and the supernatants of peripheral blood mononuclear cells
(PBMC) cultured with or without phytohaemagglutinin (PHA)
were measured by ELISA. T-bet mRNA and protein expres-
sion in PBMC cultured with or without PHA was detected by
RT-PCR and western blot, respectively.
Results: The level of IFN-c, but not IL-2 and IL-4, was
significantly higher in the supernatants of stimulated PBMC in
patients than in controls. A significantly increased T-bet
mRNA was found in VKH patients during an active uveitis
episode, but not in quiescent patients, compared to controls.
T-bet protein was detectable in VKH patients during an active
uveitis episode, but not in quiescent patients nor in the
healthy controls. Stimulation of PBMC with PHA resulted in a
marked upregulation of T-bet mRNA and protein expression
for both patients and controls with no significant difference
between the two groups.
Conclusions: Upregulation of T-bet may be associated with
the development of a Th1 mediated immune response in VKH
disease.
V
ogt-Koyanagi-Harada (VKH) disease is an autoimmune
disorder.1 Studies have revealed a strong polarised Th1
immune response in VKH patients.2–4 T-bet, a transcrip-
tional factor, has been shown to be involved in Th1 cell
development. It has been shown that T-bet promotes Th1
development and IFN-c production, and reprograms a
committed population of fully polarised Th2 cells into the
Th1 phenotype.5–9 T-bet also has a key role in controlling Th1
cell differentiation and effector functions in vivo.10 11 T-bet
has been implicated in several autoimmune diseases, includ-
ing Crohn’s disease,12 coeliac disease,13 and Behc¸et’s disease
(BD).14 15 Whether T-bet is also involved in the pathogenesis
of VKH disease is not yet known and was therefore the
subject of the study reported here. Our results show that T-
bet is increased during an active uveitis episode and may thus
have a role in the pathogenesis of this disease.
PATIENTS AND METHODS
Patients
Sixteen VKH patients (10 men and six women) with an
average age of 37 years and 16 healthy individuals (10 men
and six women) with an average age of 35 years were
included in this study. The diagnosis of VKH disease was
based on the revised criteria.16 All patients showed recurrent
intraocular inflammation and had been intermittently
treated with prednisone. Patients were referred to our centre
with uveitis, showing mutton fat keratic precipitates (KP),
cells in the anterior chamber, Dalen-Fuchs nodules, and
sunset glow fundus. The extraocular findings included
vitiligo (25%), alopecia (43.8%), dysacusis (25%), tinnitus
(56.3%), and poliosis (43.8%). Uveitis was completely
controlled in all the patients after treatment with chlor-
ambucil combined with prednisone for at least 1 year. Blood
samples were collected before this treatment (active uveitis
stage) and 3 months after stopping the treatment (inactive
uveitis stage). The blood samples were concurrently obtained
from the matched healthy individuals. All procedures
followed the tenets of the Declaration of Helsinki, and
informed consent was obtained from all patients and healthy
controls.
Preparation of samples
The blood samples were used for isolation of serum and
peripheral blood mononuclear cells (PBMC). PBMC from
each patient were divided into two aliquots: one directly for
analysis of T-bet, and the other for analysis of T-bet following
stimulation with phytohaemagglutinin (PHA). For the latter,
the PBMC were cultured in RPMI 1640 with PHA (Sigma,
MO, USA) at a concentration of 5 mg/ml for 72 hours and
subsequently used for T-bet analysis by RT-PCR and western
blot. The culture supernatants were stored at 280 C˚ for
cytokine assays.
Cytokine assays
Cytokine levels of IFN-c, IL-2, and IL-4 in the serum and
supernatants of PHA stimulated PBMC were assayed by
ELISA. Procedures were preformed according to the manu-
facturer’s instructions (R & D systems, MN, USA). The
sensitivity of IFN-c, IL-2, and IL-4 were 8 pg/ml, 7 pg/ml, and
10 pg/ml, respectively.
RT-PCR and western blot analysis
RT-PCR and western blot analysis were performed using the
reagents and procedures described previously.14
Statistical analysis
Data were reported as mean (SD). The paired t test was used
for statistical analysis. A level of p,0.05 was accepted as
statistically significant.
RESULTS
Cytokine concentrations in the serum and
supernatants of cultured PBMC
IFN-c, IL-2, or IL-4 was undetectable in the serum from
either VKH patients or controls. IFN-c concentrations in the
supernatants of stimulated PBMC during active and inactive
uveitis episodes were 645.47 (32.3) pg/ml and 565.61 (74.06)
Abbreviations: BD, Behc¸et’s disease; KP, keratic precipitates; PBMC,
peripheral blood mononuclear cells; PHA, phytohaemagglutinin; VKH,
Vogt-Koyanagi-Harada
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pg/ml, respectively, and showed no significant difference
(p.0.05). They were both significantly higher than concen-
trations in controls (28.94 (6.76) pg/ml) (p,0.001). IL-2 and
IL-4 contents were both below the detection level in the
supernatants of PHA stimulated PBMC from the patients and
controls.
Expression of T-bet mRNA in patients and controls
The sequenced polymerase chain reaction (PCR) products
showed a 99.6% homology with the known T-bet sequence.
T-bet mRNA transcripts were observed in all the tested
samples (fig 1). T-bet mRNA band intensity was normalised
by the respective b actin mRNA band and was found to be
0.74 in patients with active uveitis. This T-bet mRNA level
was significantly higher than that in patients with inactive
uveitis (0.18) as well as in controls (0.17) (p,0.001).
However, there was no significant correlation between
T-bet mRNA expression and the severity of the intraocular
inflammation in patients with active uveitis. No difference
was found between quiescent patients and controls concern-
ing this ratio. Moreover, there was no difference in this ratio
between VKH patients with (0.81) or without (0.84) active
uveitis and controls (0.82) after PHA stimulation (fig 2).
Expression of T-bet protein in patients and controls
T-bet protein was assayed using western blot. Before PHA
treatment, a protein band of approximately 62 kDa could
only be detected in the PBMC from patients with active
uveitis, but not in those from patients with inactive uveitis or
the controls (fig 3). In contrast, after PHA stimulation, all the
tested samples showed the 62 kDa band. Furthermore,
quantitative analysis indicated that the expression of T-bet
protein after stimulation was essentially identical in patients
and controls (fig 4).
DISCUSSION
Our study revealed an upregulated T-bet expression at both
mRNA and protein levels, in association with a significantly
increased IFN-c in the supernatants of PHA stimulated
PBMC, in VKH patients with active uveitis. These results
suggest that T cells in PBMC in VKH disease are apt to deviate
towards the Th1 type and that T-bet may have a role in the
pathogenesis of VKH disease.
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Figure 1 RT-PCR products of T-bet mRNA extracted from freshly
obtained PBMC of three patients before (lanes 1, 2, 3) and after (lanes 4,
5, 6) treatment and from three controls (lanes 7, 8, 9). One
representative experiment is presented out of the 16 patients with or
without active uveitis and 16 controls.
β actin
T-bet
2000
750
250
150
500
M 1 2 3 4 5 6 7 8 9
Figure 2 RT-PCR products of T-bet mRNA extracted from PHA
stimulated PBMC from three patients with active (lanes 1, 2, 3) and
inactive (lanes 4, 5, 6) uveitis and three controls (lanes 7, 8, 9). One
representative experiment is presented out of the 16 patients with or
without active uveitis and 16 controls.
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Figure 3 Western blot analysis of T-bet protein from freshly obtained
PBMC of patients and controls. A 62 kDa protein is detectable in
samples from patients with active uveitis (lanes 1, 2, 3), but not in
patients with inactive uveitis (lanes 4, 5, 6) and controls (lanes 7, 8, 9).
One representative experiment of five independent experiments is
shown.
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Figure 4 T-bet protein expression in PHA-stimulated PBMC from
patients and controls. A 62 kDa protein was detectable in all tested
samples from patients with active (lanes 1, 2) or inactive uveitis (lanes 3,
4) and controls (lanes 5, 6). One representative experiment of eight
independent experiments is shown.
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T-bet expression has been shown to be increased in
activated T cells and is the key transcriptional factor for
Th1 cell activation and cytokine production.6 8 Our findings
are in agreement with studies on T-bet expression in other
autoimmune diseases, such as Crohn’s disease,12 coeliac
disease,13 and Behc¸et’s disease (BD).14 The observation that
T-bet expression is increases in VKH patients during an active
uveitis episode, but not during inactive uveitis supports a role
of activated T cells during the pathogenesis of this disease. In
addition, our study also showed that a significantly upregu-
lated T-bet expression was readily detected in the quiescent
patients and controls after PHA stimulation. However, no
marked difference was found in the expression of T-bet in
patients with active uveitis before and after stimulation.
These results may suggest that a large number of T-bet+ cells
already exist in the patients with active uveitis, and only few
T-bet+ cells are present in patients with inactive uveitis.
Quiescent patients in that respect are similar to the controls.
Therefore, T-bet may be closely associated with activity of
VKH disease and may serve as an immunomodulatory target.
The increased T-bet expression in VKH patients with active
uveitis in this study is consistent with the results in BD
patients with active uveitis.14 It is interesting to note that
there are marked differences in clinical and pathological
features between these two uveitis entities. The similar
results in T-bet expression observed in VKH patients and BD
patients, however, suggest a common pathway involved in
their pathogenesis.
Given the fact that T-bet can be expressed in both CD4+ T
cells and B cells, future studies should address the exact
cellular origin of T-bet+ cells using multicolour FACS co-
localisation studies. The fact that T-bet upregulation is
associated with a concomitant IFN-c expression points to
the T cell as the most likely source. Whether T-bet is an
exclusive marker of cell activation during VKH is not known
and studies investigating on the correlation between T-bet
and other CD4+ cell activation markers such as CD25 and
CD69 may shed more light on this issue. Additionally, further
evidence implicating T-bet in the pathogenesis of uveitis will
involve the use of T-bet blocking reagents or T-bet knockout
mice, which may open a new venue for the treatment of
human uveitis.
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